They conducted a randomized, double blind, placebo-controlled trial in infants. Infants received enteral talactoferrin, or TLf, or placebo until their 28th day of life. Primary outcomes were bacteremia, pneumonia, urinary tract infection, meningitis and necrotizing enterocolitis. Secondary outcomes were sepsis syndrome and suspected necrotizing enterocolitis.
Researchers did not find any enteral or organ-specific adverse events to TLf. The rate of hospital-acquired infections was 50 percent lower in the TLf group compared with the placebo group. The TLf group also had fewer blood or line infections, urinary tract infections and pneumonia.
Additionally, there was no difference between the two groups in growth or neurodevelopment over a one year post-hospitalization period.
More articles on healthcare quality:
5 misdiagnosis prevention strategies for physicians
Quality of US outpatient care has not improved consistently, study finds
Hospitals with high patient experience star ratings don’t have better outcomes, new analysis finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
